INOVIO PHARMACEUTICALS INC
For the period ended Dec 31, 2023. Filed Mar 6, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 6, 2024
INO$1.45-4.0%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Stockholders' Equity
| Preferred stock · Common stock (1) · Additionalpaid-incapital · Accumulateddeficit · Accumulatedothercomprehensiveloss · Totalstockholders’equity | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Numberof shares · Amount · Numberof shares · Amount | |||||||||
| Balance at December 31, 2020 | 9 | — | 15,570,957 | $15,571 | $1,367,578,149 | $(906,196,812) | $(256,150) | $461,140,758 | |
| Issuance of common stock for cash, net of financing costs | — | — | 2,275,861 | 2,276 | 209,439,134 | — | — | 209,441,410 | |
| Conversion of December 2019 Bonds to common stock | — | — | 84,120 | 84 | 4,377,808 | — | — | 4,377,892 | |
| Exercise of stock options for cash and vesting of RSUs, net of tax payments | — | — | 184,299 | 184 | 2,057,209 | — | — | 2,057,393 | |
| Stock-based compensation | — | — | — | — | 26,336,764 | — | — | 26,336,764 | |
| Net loss | — | — | — | — | — | (303,658,710) | — | (303,658,710) | |
| Unrealized gain on short-term investments, net of tax | — | — | — | — | — | — | 4,048 | 4,048 | |
| Foreign currency translation | — | — | — | — | — | — | (30,134) | (30,134) | |
| Balance at December 31, 2021 | 9 | — | 18,115,237 | $18,115 | $1,609,789,064 | $(1,209,855,522) | $(282,236) | $399,669,421 | |
| Cumulative adjustment from adoption of ASU 2020-06 | — | — | — | — | (3,294,019) | 1,825,803 | — | (1,468,216) | |
| Issuance of common stock for cash, net of financing costs | — | — | 2,870,478 | 2,870 | 82,952,441 | — | — | 82,955,311 | |
| Exercise of stock options for cash and vesting of RSUs, net of tax payments | — | — | 105,223 | 105 | (1,114,714) | — | — | (1,114,609) | |
| Stock-based compensation | — | — | — | — | 22,555,419 | — | — | 22,555,419 | |
| Net loss | — | — | — | — | — | (279,818,065) | — | (279,818,065) | |
| Unrealized loss on short-term investments, net of tax | — | — | — | — | — | — | (390,949) | (390,949) | |
| Foreign currency translation | — | — | — | — | — | — | (25,556) | (25,556) | |
| Balance at December 31, 2022 | 9 | $— | 21,090,938 | $21,090 | $1,710,888,191 | $(1,487,847,784) | $(698,741) | $222,362,756 | |
| Issuance of common stock for legal settlement | — | — | 760,083 | 760 | 13,999,240 | — | — | 14,000,000 | |
| Issuance of common stock for cash, net of financing costs | — | — | 875,305 | 875 | 5,460,870 | 5,461,745 | |||
| Vesting of RSUs, net of tax payments | — | — | 66,749 | 67 | (466,713) | — | — | (466,646) | |
| Stock-based compensation | — | — | — | — | 11,072,486 | — | — | 11,072,486 | |
| Net loss | — | — | — | — | — | (135,117,352) | — | (135,117,352) | |
| Unrealized gain on short-term investments, net of tax | — | — | — | — | — | — | 40,060 | 40,060 | |
| Foreign currency translation | — | — | — | — | — | — | (3,920) | (3,920) | |
| Balance at December 31, 2023 | 9 | $— | 22,793,075 | $22,792 | $1,740,954,074 | $(1,622,965,136) | $(662,601) | $117,349,129 | |
(1) All share amounts in this column, including appropriate reclassifications between common stock and additional paid-in capital, have been restated to reflect the 1-for-12 reverse stock split effected in January 2024 on a retroactive basis for all periods presented.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.